Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Chile

  • End date
    Jul 31, 2023
  • participants needed
  • sponsor
    Sinovac Biotech (Chile) SpA
Updated on 7 October 2022
Accepts healthy volunteers


The purpose of this study is to evaluate the safety and immunogenicity of Influenza vaccine (Split virion), Inactivated, Quadrivalent developed by Sinovac Biotech Co., Ltd. (Sinovac-QIV) as compared to a licensed comparator in Chile, Vaxigrip Tetra™ (Vaxigrip Tetra-QIV) in individuals aged 3 years and older.


This study is a phase Ⅲ, double-blind, randomized and active-controlled clinical trial to evaluate the safety and immunogenicity of Influenza vaccine (Split virion), Inactivated, Quadrivalent developed by Sinovac Biotech Co., Ltd. (Sinovac-QIV) as compared to a licensed comparator in Chile, Vaxigrip Tetra™ (Vaxigrip Tetra-QIV) in individuals aged 3 years and older. Subjects will be randomized 1:1 to received either Sinovac-QIV or Vaxigrip Tetra-QIV. Vaccine-primed subjects will receive one 0.5ml dose of Sinovac-QIV or Vaxigrip Tetra-QIV on day 0. Vaccine-unprimed subjects will receive two 0.5ml doses of Sinovac-QIV or Vaxigrip Tetra-QIV and day 0 and day 28, respectively. Subjects who are 3-8 years of age had prior receipt of ≥2 doses of influenza vaccine at least 4 weeks apart or who are ≥9 years old are considered "vaccine-prime". Subjects who are 3-8 years of age had prior receipt of <2 dose of influenza vaccine are considered "vaccine-unprimed".

Condition Seasonal Influenza
Treatment Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Control Quadrivalent influenza virus vaccine
Clinical Study IdentifierNCT05431725
SponsorSinovac Biotech (Chile) SpA
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Volunteers age 3 years and older, in good health or medically stable
Written informed consent obtained from subjects or/and legal guardian
No receipt of influenza vaccines within 6 months or plans to receive any influenza vaccines during the study
Female subjects of non-child bearing may be enrolled in the study. Non-child bearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or premenarche or postmenopausal (defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause)
Female subjects of child bearing potential may be enrolled in the study, if the subject
Has a negative pregnancy test on the day of the first dose (day 0)
Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose and until at least 28 days after vaccination

Exclusion Criteria

History of seasonal influenza within 6 months prior to the study entry
Axillary temperature ≥37.3℃
History of Guillain-Barré syndrome within 6 weeks of receipt of prior influenza vaccine
History of allergy to any vaccine, or any ingredient of the experimental vaccine
Serious adverse reaction(s) to the vaccine, such as urticaria, dyspnea or angioneurotic edem etc
History of serious neurological disorder (such as epilepsy, convulsions etc.) or a mental illness
Autoimmune disease or immunodeficiency/immunosuppressive, or any immunosuppressant receipt within 6 months prior to the study entry
Significant chronic illnesses that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion (may include, but are not limited to cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, liver or kidney disorders, HIV infection or malignant tumor
Acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders
Absence of spleen, functional absence of spleen, and absence or removal of spleen under any circumstances
Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities), or obvious bruising or coagulation disorders
Alcoholism or history of drug abuse;
Acute disease or acute stage of chronic disease within 7 days prior to study entry
Received blood products within 3 months prior to study entry
Received any live attenuated vaccine within 14 days prior to study entry or any subunit vaccine or inactivated vaccine within 7 days prior to study entry
Pregnant women or lactating women
Subjects participate other clinical trials (licensed or unlicensed vaccines, drugs, organisms, devices, blood products or drugs) during the study period
Any other factors which are unsuitable for participation in the clinical trial as judged by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note